Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

Glucokinase plays a central role in glucose homeostasis and small molecule activators of the glucokinase enzyme have been the subject of significant pharmaceutical research in the quest for agents capable of delivering improved glycaemic control. Here we describe our medicinal chemistry campaign to improve on our previously described development candidate in this area, AZD1092, focussed on removal of Ames liability and improved permeability characteristics. This work culminated in the superior compound AZD1656 which has progressed to phase 2 clinical trials.

[1]  D. Mckerrecher,et al.  Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life. , 2011, Bioorganic & medicinal chemistry letters.

[2]  Michael J. Waring,et al.  Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators , 2011 .

[3]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[4]  M. Coghlan,et al.  Small molecule glucokinase activators as novel anti-diabetic agents. , 2005, Biochemical Society transactions.

[5]  Catrin Hasselgren,et al.  Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2. , 2011, Journal of the American Chemical Society.

[6]  M. Waring.  Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[7]  M. Tadayyon,et al.  Insulin sensitisation in the treatment of Type 2 diabetes , 2003, Expert opinion on investigational drugs.

[8]  F. Matschinsky.  Regulation of Pancreatic β-Cell Glucokinase: From Basics to Therapeutics , 2002 .

[9]  Giuseppe d'Annunzio,et al.  Insights into the Structure and Regulation of Glucokinase from a Novel Mutation (V62M), Which Causes Maturity-onset Diabetes of the Young* , 2005, Journal of Biological Chemistry.

[10]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[11]  M. Coghlan,et al.  Glucokinase activators in diabetes management , 2008, Expert opinion on investigational drugs.

[12]  M. Fyfe,et al.  Glucokinase activators as potential antidiabetic agents possessing superior glucose lowering efficacies , 2009, Drugs of the Future.

[13]  Michael J. Waring,et al.  Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092 , 2011 .

[14]  Andrew G Leach,et al.  Reaction energies computed with density functional theory correspond with a whole organism effect; modelling the Ames test for mutagenicity. , 2009, Chemical communications.

[15]  E. Kilgour,et al.  PDH kinase inhibitors: a novel therapy for Type II diabetes? , 2005, Biochemical Society transactions.

[16]  H. Najafi,et al.  Glucokinase and glucose homeostasis: proven concepts and new ideas. , 2005, Biochemical Society transactions.

[17]  F. Matschinsky,et al.  Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.

[18]  Craig S Donald,et al.  Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. , 2006, Bioorganic & medicinal chemistry letters.

[19]  Scott Boyd,et al.  Discovery, synthesis and biological evaluation of novel glucokinase activators. , 2005, Bioorganic & medicinal chemistry letters.